Sanofi (NASDAQ:SNY) Now Covered by Analysts at The Goldman Sachs Group

Analysts at The Goldman Sachs Group started coverage on shares of Sanofi (NASDAQ:SNY - Get Free Report) in a research report issued on Friday, MarketBeat.com reports. The firm set a "neutral" rating and a $65.00 price target on the stock. The Goldman Sachs Group's target price indicates a potential upside of 16.15% from the company's current price.

A number of other research firms also recently commented on SNY. Deutsche Bank Aktiengesellschaft upgraded Sanofi from a "sell" rating to a "hold" rating in a research note on Thursday, January 30th. StockNews.com lowered Sanofi from a "buy" rating to a "hold" rating in a research report on Thursday, December 12th. Finally, Sanford C. Bernstein raised Sanofi to a "strong-buy" rating in a research report on Thursday, January 30th. Three investment analysts have rated the stock with a hold rating, one has given a buy rating and two have given a strong buy rating to the company's stock. Based on data from MarketBeat, Sanofi has an average rating of "Moderate Buy" and a consensus target price of $62.50.

Sanofi Stock Down 1.7 %

SNY stock traded down $0.94 during midday trading on Friday, hitting $55.96. 687,873 shares of the company's stock were exchanged, compared to its average volume of 2,264,797. The firm has a 50 day moving average price of $54.55 and a 200-day moving average price of $52.85. Sanofi has a 12-month low of $45.22 and a 12-month high of $60.12. The stock has a market capitalization of $142.02 billion, a price-to-earnings ratio of 22.47, a price-to-earnings-growth ratio of 1.01 and a beta of 0.58. The company has a current ratio of 1.46, a quick ratio of 1.14 and a debt-to-equity ratio of 0.15.

Remove Ads

Sanofi (NASDAQ:SNY - Get Free Report) last issued its quarterly earnings results on Thursday, January 30th. The company reported $0.70 earnings per share (EPS) for the quarter, hitting analysts' consensus estimates of $0.70. Sanofi had a net margin of 12.77% and a return on equity of 25.61%. On average, analysts anticipate that Sanofi will post 4.36 EPS for the current year.

Hedge Funds Weigh In On Sanofi

A number of hedge funds and other institutional investors have recently bought and sold shares of SNY. Abel Hall LLC boosted its position in shares of Sanofi by 1.8% during the 4th quarter. Abel Hall LLC now owns 10,990 shares of the company's stock valued at $530,000 after purchasing an additional 194 shares in the last quarter. Providence Capital Advisors LLC lifted its stake in Sanofi by 0.4% during the fourth quarter. Providence Capital Advisors LLC now owns 55,001 shares of the company's stock valued at $2,653,000 after purchasing an additional 201 shares during the last quarter. Keudell Morrison Wealth Management boosted its holdings in Sanofi by 1.7% during the fourth quarter. Keudell Morrison Wealth Management now owns 12,928 shares of the company's stock worth $624,000 after buying an additional 217 shares in the last quarter. Bailard Inc. grew its position in Sanofi by 1.4% in the fourth quarter. Bailard Inc. now owns 16,359 shares of the company's stock worth $789,000 after buying an additional 220 shares during the last quarter. Finally, Old Port Advisors increased its holdings in shares of Sanofi by 0.6% in the fourth quarter. Old Port Advisors now owns 36,704 shares of the company's stock valued at $1,770,000 after buying an additional 232 shares in the last quarter. 14.04% of the stock is currently owned by institutional investors and hedge funds.

Sanofi Company Profile

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.